| Cardiotoxicity of anticancer treatments: epidemiology, detection, and management G Curigliano, D Cardinale, S Dent, C Criscitiello, O Aseyev, D Lenihan, ... CA: a cancer journal for clinicians 66 (4), 309-325, 2016 | 757 | 2016 |
| A randomised trial of 4-versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer M Clemons, M Ong, C Stober, S Ernst, C Booth, C Canil, M Mates, ... European Journal of Cancer 142, 132-140, 2021 | 56 | 2021 |
| Cardiac myxomas: clinical presentation, diagnosis and management AG Griborio-Guzman, OI Aseyev, H Shah, M Sadreddini Heart 108 (11), 827-833, 2022 | 50 | 2022 |
| Right heart function deteriorates in breast cancer patients undergoing anthracycline-based chemotherapy KE Boczar, O Aseyev, J Sulpher, C Johnson, IG Burwash, M Turek, S Dent, ... Echo Research & Practice 3 (3), 79-84, 2016 | 46 | 2016 |
| Effect of obesity, dyslipidemia, and diabetes on trastuzumab-related cardiotoxicity in breast cancer P Kosalka, C Johnson, M Turek, J Sulpher, A Law, J Botros, S Dent, ... Current Oncology 26 (3), 314-321, 2019 | 41 | 2019 |
| A multicentre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage … M Clemons, D Fergusson, D Simos, M Mates, A Robinson, N Califaretti, ... Annals of Oncology 31 (7), 951-957, 2020 | 36 | 2020 |
| Review on the clinical use of eribulin mesylate for the treatment of breast cancer O Aseyev, JM Ribeiro, F Cardoso Expert Opinion on Pharmacotherapy 17 (4), 589-600, 2016 | 28 | 2016 |
| Clinical experience of patients referred to a multidisciplinary cardio-oncology clinic: an observational cohort study C Kappel, M Rushton, C Johnson, O Aseyev, G Small, A Law, J Ivars, ... Current Oncology 26 (3), 322-327, 2019 | 26 | 2019 |
| A randomized trial comparing four-weekly versus 12-weekly administration of bone-targeted agents (denosumab, zoledronate, or pamidronate) in patients with bone metastases from … MJ Clemons, M Ong, C Stober, DS Ernst, CM Booth, CM Canil, M Mates, ... Journal of Clinical Oncology 37 (15_suppl), 11501-11501, 2019 | 12 | 2019 |
| Two-year results of a randomised trial comparing 4-versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer M Clemons, M Liu, C Stober, G Pond, MJ Alzahrani, M Ong, S Ernst, ... Journal of Bone Oncology 30, 100388, 2021 | 10 | 2021 |
| Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA. 21 experience SF Dent, J Botros, M Rushton, O Aseyev, MN Levine, WR Parulekar, ... Breast Cancer Research and Treatment 184, 733-741, 2020 | 9 | 2020 |
| A randomized trial comparing 3-versus 4-monthly cardiac monitoring in patients receiving trastuzumab-based chemotherapy for early breast cancer S Dent, D Fergusson, O Aseyev, C Stober, G Pond, AA Awan, SF McGee, ... Current Oncology 28 (6), 5073-5083, 2021 | 5 | 2021 |
| How Canadian oncologists use oncotype DX for treatment of breast cancer patients X Zhu, S Dent, L Paquet, T Zhang, D Tesolin, N Graham, O Aseyev, ... Current Oncology 28 (1), 800-812, 2021 | 5 | 2021 |
| A pragmatic, randomised, multicentre trial comparing 4-weekly vs. 12-weekly administration of bone-targeted agents (denosumab, zoledronate or pamidronate) in patients with bone … M Clemons, C Stober, M Mates, AA Joy, A Robinson, J Hilton, ... Annals of Oncology 30, iii73, 2019 | 4 | 2019 |
| Cost-effectiveness analysis of 12-versus 4-weekly administration of bone-targeted agents in patients with bone metastases from breast and castration-resistant prostate cancer MM Tu, M Clemons, C Stober, A Jeong, L Vandermeer, M Mates, ... Current Oncology 28 (3), 1847-1856, 2021 | 3 | 2021 |
| Access to oncology medicines in Canada: consensus forum for recommendations for improvement SR Sehdev, NSB Rawson, OI Aseyev, CJ Buick, MO Butler, S Edwards, ... Current Oncology 31 (4), 1803-1816, 2024 | 2 | 2024 |
| Abstract P2-07-06: Obesity, dyslipidemia, and diabetes as risk factors for trastuzumab-related cardiotoxicity in breast cancer patients O Aseyev, C Johnson, M Turek, E Stadnick, A Law, N Gosh, S Dent Cancer Research 77 (4_Supplement), P2-07-06-P2-07-06, 2017 | 2 | 2017 |
| Peculiarities of academic motivation of the students of high medical school. IM Bondarenko, VF Zavizion, VS Kyslytsyna, OI Aseyev, KO Dmytrenko, ... Medicni Perspektivi 20 (2), 17, 2015 | 2 | 2015 |
| When tissue is not the only issue: Poorly differentiated lung squamous-cell carcinoma with adrenal, costochondral, and cardiac metastases–case report M Clark, AG Griborio-Guzman, NP Burute, S Lubbers, ML Anthes, ... Frontiers in Oncology 13, 1117024, 2023 | 1 | 2023 |
| Abstract P2-06-09: Prediction of relapse in patients with locally advanced breast cancer after neoadjuvant treatment O Aseyev, L Simmonds, M Gertler, S Dent, S Verma Cancer Research 77 (4_Supplement), P2-06-09-P2-06-09, 2017 | 1 | 2017 |
